Overview

Artefill for the Treatment of HIV-associated Facial Lipoatrophy

Status:
Completed

Trial end date:
2019-11-01

Target enrollment:

Participant gender:

Summary

Artefill is an injectable facial filler device that is currently approved by the FDA for the correction of nasolabial folds. This study seeks to examine the use of Artefill in the treatment of HIV associated facial lipoatrophy. Facial lipoatrophy (facial fat loss) related to HIV is a stigmatizing condition characterized by loss of facial fat, most notably in the cheeks and temples.

Phase:

Phase 1

Details

Lead Sponsor:

Gerald Pierone, Jr. M.D.

Collaborator:

Suneva Medical, Inc.

Treatments:

Polymethyl Methacrylate